On December 29, 2023, HOOKIPA Pharma Inc. received communication from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-3, which was filed on December 22, 2023. The SEC informed HOOKIPA Pharma that it has not reviewed and will not review the registration statement. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Doris Stacey Gama was designated as the contact person at the SEC for any further inquiries from HOOKIPA Pharma.

On December 29, 2023, HOOKIPA Pharma Inc. received communication from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-3, which was filed on December 22, 2023. The SEC informed HOOKIPA Pharma that it has not reviewed and will not review the registration statement. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Doris Stacey Gama was designated as the contact person at the SEC for any further inquiries from HOOKIPA Pharma.